Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Allgens Medical Technology Co. Ltd. (688613.SS)
Beijing, CN
Allgens Medical Technology Co. Ltd. operates as a medical device firm, concentrating on the development and production of sophisticated biomimetic synthetic bone graft systems. These innovative solutions are engineered for global deployment in areas where both cancellous (spongy) and cortical (dense outer layer) bone tissues have been compromised. The company's diverse product portfolio includes key offerings such as BonGold, a mineralized collagen scaffold designed for bone grafting procedures; the high-performance Alligator bone marrow aspirator; and OssaNova, a mineralized collagen-based material utilized for bone filling and augmentation. These products are broadly applied across a spectrum of orthopedic and skeletal repair interventions throughout the human anatomy. Allgens Medical Technology Co. Ltd. was established in 2004 and is headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.87% | -11.05% | -17.96% | -32.13% | -16.05% | -16.79% | -10.72% | -33.98% | -87.32% | -82.21% | -82.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+8.5% Q1'26: +14.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+211.1% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+2.6% Q1'26: -66.5% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-1.4% Q1'26: -3.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-0.7% Q1'26: -0.8% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-6.5% ★ Q1'26: +35.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.44× ★ Q1'26: -1.92× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
236.06M
est: 253.00M (-6.7%)
|
245.31M
est: 245.00M (+0.1%)
|
226.48M
est: 294.00M (-23.0%)
|
206.03M
est: 207.00M (-0.5%)
|
223.51M
est: 270.00M (-17.2%)
|
355.00M
355.00M – 355.00M
+31.5% YoY
|
470.00M
470.00M – 470.00M
+32.4% YoY
|
| EBITDA |
146.24M
est: 100.21M (+45.9%)
|
112.26M
est: 97.05M (+15.7%)
|
67.03M
est: 116.45M (-42.4%)
|
11.06M
est: 63.71M (-82.6%)
|
25.08M
est: 83.11M (-69.8%)
|
109.27M
109.27M – 109.27M
+31.5% YoY
|
144.67M
144.67M – 144.67M
+32.4% YoY
|
| EBIT |
135.49M
est: 80.88M (+67.5%)
|
98.07M
est: 78.33M (+25.2%)
|
52.24M
est: 93.99M (-44.4%)
|
-5.96M
est: 48.08M (-112.4%)
|
-3.17M
est: 62.71M (-105.1%)
|
82.45M
82.45M – 82.45M
+31.5% YoY
|
109.16M
109.16M – 109.16M
+32.4% YoY
|
| Net Income |
120.78M
est: 146.32M (-17.5%)
|
95.22M
est: 99.89M (-4.7%)
|
54.23M
est: 77.38M (-29.9%)
|
-12.66M
est: 6.58M (-292.6%)
|
13.84M
est: 40.77M (-66.1%)
|
64.44M
64.44M – 64.44M
+58.1% YoY
|
96.00M
96.00M – 96.00M
+49.0% YoY
|
| SGA |
53.35M
est: 52.97M (+0.7%)
|
69.95M
est: 51.30M (+36.4%)
|
122.04M
est: 61.56M (+98.3%)
|
123.60M
est: 76.13M (+62.4%)
|
42.21M
est: 99.29M (-57.5%)
|
130.55M
130.55M – 130.55M
+31.5% YoY
|
172.84M
172.84M – 172.84M
+32.4% YoY
|
| EPS |
1.01
est: 1.04 (-2.9%)
|
0.71
est: 0.71 (+0.0%)
|
0.41
est: 0.55 (-25.5%)
|
-0.09
est: 0.05 (-280.0%)
|
0.10
est: 0.31 (-67.7%)
|
0.49
0.49 – 0.49
+58.1% YoY
|
0.73
0.73 – 0.73
+49.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fuzhai Cui | Founder & Chief Scientist | — | male |
| Guofeng Tian | Deputy GM & Director | — | male |
| Ling Wang | Head of Finance | — | female |
| Menglong Cui | GM & Director | — | male |
| Tianxi Song | Director, Deputy GM & Core Technical Personnel | — | male |
| Wanlan Huang | Founder, Deputy GM & Director | — | female |
| Xiaoying Miao | Accounting Supervisor | — | — |
| Yongqiang Wu | Chairman of the Board of Supervisors & Human Resource Director | — | male |
| Zhiye Qiu | Deputy GM, Secretary of the Board of Directors & Core Technical Personnel | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688613.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
